Investigation of a Novel Gene Expression Test (ASGES or Corus CAD) for Diagnosis of Obstructive Coronary Artery Disease
Sponsored by CardioDx
About this trial
Last updated 6 years ago
Study ID
CDX_000013
Status
Completed
Type
Observational
Placebo
No
Accepting
21+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 12 years ago
What is this trial about?
The objective of this study is to collect data on the commercial use of Corus CAD
(Age/Sex/Gene Expression score - ASGES) blood test to evaluate the clinical referral
patterns of Primary Care Physicians after receipt of their patients' Corus Score, and to
better understand patient management patterns for clinicians ordering the test.
What are the participation requirements?
Inclusion Criteria
1. Patients with symptoms suggestive of CAD, including typical or atypical angina or angina equivalent
2. The patient has signed the appropriate Institutional Review Board approved Informed Consent Form
Exclusion Criteria
1. History of myocardial infarction
2. Current MI or acute coronary syndrome
3. Current New York Heart Association (NYHA) class III or IV congestive heart failure symptoms
4. Any previous coronary Revascularization
5. Any individuals with:
- Diabetes
- Suspected unstable angina
- Systemic infections
- Systemic inflammatory conditions
6. Any individuals currently taking:
- Steroids
- Immunosuppressive agents
- Chemotherapeutic agents
7. Recipient of any organ transplant